miR-17-5p has also been associated with the regulation of checkpoint inhibitor molecule PD-L1: BRAF inhibitor resistant melanomas bear increased expression of PD-L1; such increase is inversely correlated with patient plasmatic levels of mir-17-5p which has PD-L1 as a direct post-transcriptional target [85]. Here, BRAF is linked to melanoma.